Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of "Buy" from Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have been given an average rating of "Buy" by the six analysts that are presently covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $43.33.

Several brokerages have recently weighed in on BCAX. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a "strong-buy" rating in a research report on Tuesday, November 5th. Stifel Nicolaus assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a "buy" rating and a $47.00 target price for the company. TD Cowen started coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued a "buy" rating on the stock. Morgan Stanley started coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 price target for the company. Finally, Rodman & Renshaw began coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They set a "buy" rating and a $48.00 price objective on the stock.

Insider Transactions at Bicara Therapeutics

In related news, major shareholder James E. Flynn bought 70,000 shares of the company's stock in a transaction on Tuesday, September 17th. The shares were bought at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the transaction, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. This trade represents a 8.46 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the business's stock in a transaction on Monday, September 16th. The shares were bought at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the purchase, the director now directly owns 4,303,418 shares in the company, valued at $77,461,524. This represents a 74.20 % increase in their position. The disclosure for this purchase can be found here.

Institutional Investors Weigh In On Bicara Therapeutics

A number of large investors have recently made changes to their positions in BCAX. RA Capital Management L.P. acquired a new position in Bicara Therapeutics in the 3rd quarter worth approximately $177,169,000. FMR LLC acquired a new stake in Bicara Therapeutics during the 3rd quarter valued at approximately $57,913,000. Braidwell LP purchased a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at $42,219,000. Janus Henderson Group PLC acquired a new stake in shares of Bicara Therapeutics in the third quarter worth $30,329,000. Finally, Baker BROS. Advisors LP purchased a new position in shares of Bicara Therapeutics during the third quarter worth $21,225,000.

Bicara Therapeutics Stock Down 0.8 %

Shares of Bicara Therapeutics stock traded down $0.17 during trading hours on Friday, hitting $20.79. The company's stock had a trading volume of 189,395 shares, compared to its average volume of 317,384. Bicara Therapeutics has a 12-month low of $17.41 and a 12-month high of $28.09. The stock has a 50 day moving average price of $22.31.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, equities analysts expect that Bicara Therapeutics will post -2.89 earnings per share for the current year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.